全球病毒载体和质体DNA生产市场规模、份额、趋势和成长分析报告（2026-2034年）

病毒载体和质体DNA生产市场预计将从2025年的85亿美元成长到2034年的469.5亿美元，2026年至2034年的复合年增长率为20.92%。

受基因疗法、细胞疗法和先进生物製药日益普及的推动，全球病毒载体和质体DNA生产市场正经历快速成长。慢病毒和腺病毒等病毒载体是基因编辑和免疫疗法应用中携带遗传物质的关键载体。 CAR-T疗法和罕见疾病治疗临床试验的激增显着提高了对高品质载体和质体DNA生产能力的需求。

关键成长要素包括生物技术研发投入的增加、基因疗法监管核准的扩大，以及生物技术公司与合约研发生产机构（CDMO）之间合作的加强。可扩展生产平台和纯化技术的进步正在提升生产效率。政府和私人投资者也在资助基础设施建设，以解决供应瓶颈并加速商业化。

随着全球基因治疗研发管线的不断扩展，市场预计将迎来强劲成长。从小小规模临床生产向大规模商业化生产的转变将创造巨大的机会。悬浮细胞培养系统、自动化和闭环生产流程的创新可望提高产量并降低成本，从而支持病毒载体和质体DNA生产产业的长期发展。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球病毒载体与质体DNA生产市场：依载体类型划分

• 市场分析、洞察与预测
• 腺病毒
• 逆转录病毒
• 腺结合病毒（AAV）
• 慢病毒
• 质体
• 其他的

第五章 全球病毒载体与质体DNA生产市场：依工作流程划分

• 市场分析、洞察与预测
• 上游工程製造
• 下游製造

第六章 全球病毒载体与质体DNA生产市场：依应用划分

• 市场分析、洞察与预测
• 反义和RNAi疗法
• 基因治疗
• 细胞疗法
• 疫苗学
• 出于研究目的

第七章 全球病毒载体与质体DNA生产市场：依最终用途划分

• 市场分析、洞察与预测
• 製药和生物製药公司
• 研究机构

第八章 全球病毒载体与质体DNA生产市场：依疾病分类

• 市场分析、洞察与预测
• 癌症
• 遗传性疾病
• 感染疾病
• 其他的

第九章 全球病毒载体与质体DNA生产市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific
  • Merck KGaA
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Catalent Inc
  • Wuxi Biologics
  • Cobra Biologics
  • Takara Bio Inc
  • BioMarin Pharmaceutical
  • RegenxBioInc
  • Miltenyi Biotec GmbH
  • Sirion Biotech GmbH
  • Batavia Biosciences
  • Waisman Biomanufacturing
  • Genezen Laboratories

The Viral Vector & Plasmid DNA Manufacturing Market size is expected to reach USD 46.95 Billion in 2034 from USD 8.50 Billion (2025) growing at a CAGR of 20.92% during 2026-2034.

The Global Viral Vector & Plasmid DNA Manufacturing Market has witnessed rapid expansion driven by the growing adoption of gene therapies, cell therapies, and advanced biologics. Viral vectors such as lentivirus and adenovirus are essential for delivering genetic material in gene editing and immunotherapy applications. The surge in clinical trials for CAR-T therapies and rare disease treatments has significantly increased demand for high-quality vector and plasmid DNA production capabilities.

Key growth drivers include rising investment in biotechnology research, increasing regulatory approvals for gene-based therapies, and expanding partnerships between biotech firms and contract development and manufacturing organizations (CDMOs). Technological advancements in scalable manufacturing platforms and improved purification techniques have enhanced production efficiency. Governments and private investors are also funding infrastructure development to address supply constraints and accelerate commercialization.

Looking ahead, the market is poised for strong growth as gene therapy pipelines continue to expand globally. The transition from small-scale clinical manufacturing to large-scale commercial production will create significant opportunities. Innovations in suspension cell culture systems, automation, and closed manufacturing processes are expected to improve yields and reduce costs, supporting long-term expansion of the viral vector and plasmid DNA manufacturing industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vector Type

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End-use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, Lonza, Fujifilm Diosynth Biotechnologies, Catalent Inc, Wuxi Biologics, Cobra Biologics, Takara Bio Inc, BioMarin Pharmaceutical, RegenxBio, Inc, Miltenyi Biotec GmbH, Sirion Biotech GmbH, Batavia Biosciences, Waisman Biomanufacturing, Genezen Laboratories

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Vector Type
• 4.2. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Retrovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Adeno-Associated Virus (AAV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Plasmids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Upstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Downstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Antisense & RNAi Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY DISEASE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Disease
• 8.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Vector Type
  • 9.2.2 By Workflow
  • 9.2.3 By Application
  • 9.2.4 By End-use
  • 9.2.5 By Disease
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Vector Type
  • 9.3.2 By Workflow
  • 9.3.3 By Application
  • 9.3.4 By End-use
  • 9.3.5 By Disease
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Vector Type
  • 9.4.2 By Workflow
  • 9.4.3 By Application
  • 9.4.4 By End-use
  • 9.4.5 By Disease
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Vector Type
  • 9.5.2 By Workflow
  • 9.5.3 By Application
  • 9.5.4 By End-use
  • 9.5.5 By Disease
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Vector Type
  • 9.6.2 By Workflow
  • 9.6.3 By Application
  • 9.6.4 By End-use
  • 9.6.5 By Disease
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific
  • 11.2.2 Merck KGaA
  • 11.2.3 Lonza
  • 11.2.4 Fujifilm Diosynth Biotechnologies
  • 11.2.5 Catalent Inc
  • 11.2.6 Wuxi Biologics
  • 11.2.7 Cobra Biologics
  • 11.2.8 Takara Bio Inc
  • 11.2.9 BioMarin Pharmaceutical
  • 11.2.10 RegenxBioInc
  • 11.2.11 Miltenyi Biotec GmbH
  • 11.2.12 Sirion Biotech GmbH
  • 11.2.13 Batavia Biosciences
  • 11.2.14 Waisman Biomanufacturing
  • 11.2.15 Genezen Laboratories